AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$BBIO

Kumar Neil sold $2.9M of BBIO

Kumar Neil (Chief Executive Officer) sold 34,980 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $82.53 ($81.15–$83.77, $2.89M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Aug 20, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BBIO
Bearish
medium confidence
Mentioned
$BBIO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIOBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a negative signal, though it could simply be a planned liquidity event.

02

Market read

Insider sales are closely monitored; this filing provides fresh data for traders evaluating BBIO.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑20

Background

Form 4 filing reveals a CEO's open‑market sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$BBIOBearishMedium confidence
Context

CEO Kumar Neil sold 34,980 shares for $2.9M via a 10b5-1 plan, reducing his stake to 243,327 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Insider sales by a CEO are watched closely; the $2.9M amount is material for a mid‑cap biotech, but not large enough to trigger a sharp move.

Market effects

Sector

May raise concerns for biotech sector investors tracking insider activity.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • company
    BridgeBio Pharma, Inc.

    Biotech firm listed on Nasdaq (BBIO).

  • person
    Kumar Neil

    Chief Executive Officer of BridgeBio Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

OCT 7
$BBIOMedAI 9/10

BridgeBio Pharma stock rating reiterated at Buy by Canaccord

Canaccord reiterated a Buy rating and $106 price target for BridgeBio Pharma (BBIO) after positive cardiac data from its LGMD2I/R9 treatment program. The company's stock trades at $66.96, below the target. Analysts maintain a Strong Buy consensus with targets ranging from $80 to $156. BridgeBio estimates a 90% success probability and peak sales of $1.3B by 2034 for the treatment.

investing.com2 min
OCT 6
$BBIOHigh

FDA Accepts BridgeBio's Infigratinib NDA For Priority Review

BridgeBio Pharma (BBIO) announced the FDA accepted its NDA for infigratinib to treat achondroplasia in children, granting Priority Review. The PDUFA target date is February 4, 2027. The NDA is backed by positive Phase 3 study results showing significant improvements in height velocity and body proportionality. BBIO shares rose 1.65% on Friday and are up 3.42% in premarket trading.

rttnews.com2 min
OCT 6
$BBIOHigh

H.C. Wainwright reiterates Buy on BridgeBio stock, cites cardiac data

H.C. Wainwright reiterated a Buy rating and $120 price target on BridgeBio Pharma (BBIO) after positive cardiac data from its muscular dystrophy treatment. The stock is currently at $66.14, with analysts maintaining a Strong Buy consensus and targets ranging from $80 to $157. BridgeBio reported 202% revenue growth and 94% gross margins over the last year, according to InvestingPro.

investing.com1 min
OCT 6
$BBIOMed

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

BridgeBio Pharma (BBIO) announced FDA acceptance of its NDA for oral infigratinib to treat children with achondroplasia, with a Priority Review and PDUFA target date of February 4, 2027. The PROPEL 3 trial met primary and key secondary endpoints, showing significant improvements in height velocity and body proportionality. If approved, it would be the first oral therapy for this condition.

globenewswire.com3 min